AKR1D1 congenital bile acid synthesis defect is a very rare inherited liver and metabolism disease. Its usual formal name is congenital bile acid synthesis defect type 2, or CBAS2. It happens when a child receives harmful changes in both copies of the AKR1D1 gene. This gene helps the liver make an enzyme that is needed to build normal primary bile acids. Without enough normal bile acids, bile flow becomes weak, harmful abnormal bile acid intermediates build up, fat is not absorbed well, and the liver can become damaged over time. The illness often starts in infancy with cholestasis, jaundice, poor growth, and vitamin deficiency.
AKR1D1 congenital bile acid synthesis defect is also called congenital bile acid synthesis defect type 2 or Δ4-3-oxosteroid 5β-reductase deficiency. It is a very rare inherited liver disease. The body cannot make normal primary bile acids well. Because of that, bile flow becomes weak, toxic bile acid intermediates can build up, and the body cannot absorb fat and vitamins A, D, E, and K properly. Babies often develop jaundice, poor growth, bleeding problems, and liver damage early in life. Early diagnosis matters because bile acid replacement can be life-saving. 1 2 3
In very simple words, the liver is missing an important chemical step. The AKR1D1 enzyme normally helps change cholesterol into useful bile acids. When that step fails, the liver makes too little normal bile acid and too many abnormal bile chemicals. These abnormal chemicals can injure liver cells, while the lack of normal bile acids reduces bile flow and causes fat malabsorption. That is why many patients have liver disease and vitamin deficiency at the same time. 4 3 5
This disorder is important because it is rare but treatable, especially when doctors recognize it early. In many children, the first clues are prolonged jaundice, enlarged liver, pale stools, poor weight gain, easy bleeding from vitamin K deficiency, and steatorrhea, which means greasy or oily stool from poor fat absorption. Reviews of bile acid synthesis disorders also note that gamma-glutamyl transferase, called GGT, can be normal even when cholestasis is present, which can help doctors think about this diagnosis.
Another names
Other names used for this disease include congenital bile acid synthesis defect type 2, CBAS2, BAS defect type 2, and cholestasis with delta(4)-3-oxosteroid 5-beta-reductase deficiency. Some papers also describe it as Δ4-3-oxosteroid 5β-reductase deficiency or AKR1D1 deficiency. These names describe the same core problem: the liver cannot complete an early step in bile acid production because the AKR1D1 enzyme does not work well enough.
Types in list view
There are not many separate clinical “types” inside AKR1D1 deficiency itself. In simple language, doctors usually think of it in a few practical ways. Type 1: classic infantile form, where symptoms begin in the first months of life with jaundice and cholestasis. Type 2: severe neonatal form, where liver failure can appear very early. Type 3: milder or later-presenting form, where diagnosis may be delayed because signs are less obvious. Type 4: genotype-based form, where the disease is described by the exact AKR1D1 variants found in the child. These are practical ways of describing the same disease, not officially separate named diseases.
Causes
Strictly speaking, this disease has one direct cause: a child has biallelic pathogenic variants in AKR1D1, meaning both gene copies are affected. The 20 points below are the main genetic causes and inheritance situations that explain why the disease happens, rather than 20 unrelated diseases.
-
The main cause is a harmful change in the AKR1D1 gene that reduces or destroys enzyme activity in the bile acid pathway. This blocks normal bile acid production.
-
A child may inherit one harmful AKR1D1 variant from the mother and one from the father. This is the usual autosomal recessive pattern.
-
The child may have two identical pathogenic variants, called a homozygous state. This is common in some families with shared ancestry.
-
The child may have two different harmful variants, called compound heterozygous disease. Both still damage the same gene.
-
A missense mutation can change one amino acid in the AKR1D1 enzyme and make the protein weak or unstable.
-
A nonsense mutation can create a premature stop signal, so the enzyme becomes too short to work normally.
-
A splice-site mutation can make the cell build the gene message in the wrong way, leading to an abnormal enzyme.
-
A small deletion in AKR1D1 can remove part of the coding sequence and disrupt the enzyme.
-
A small insertion can shift the reading frame and produce a faulty protein.
-
A frameshift mutation changes the downstream protein sequence and usually causes major loss of function.
-
Some variants make the enzyme fold badly, so the cell breaks it down too early.
-
Some variants leave the enzyme present but very low in activity, which still causes disease because bile acid synthesis needs enough enzyme function.
-
Some disease-causing variants interfere with the enzyme’s binding to its substrate, so the blocked pathway cannot move forward.
-
Some variants reduce the enzyme’s stability inside liver cells, so it does not last long enough to do its job.
-
A family history of the same rare disorder increases the chance that a new baby may inherit the same two harmful variants.
-
Carrier parents usually stay healthy, but when both are carriers, each pregnancy has a risk of an affected child.
-
Consanguinity, meaning parents are biologically related, raises the chance that both carry the same rare recessive AKR1D1 variant.
-
A founder variant in a family or small population can make the disorder appear in more than one relative.
-
The biochemical cause after the gene defect is failure to make enough normal primary bile acids, especially the bile acids needed to support bile flow and fat absorption.
-
Another part of the disease mechanism is the build-up of abnormal bile acid intermediates, which can be toxic to the liver and help drive progressive liver disease.
Symptoms
-
Jaundice is one of the most common symptoms. The skin and eyes become yellow because bile is not moving and bilirubin collects in the body.
-
Cholestasis means reduced bile flow from the liver. It is the main disease pattern in AKR1D1 deficiency and explains many other symptoms.
-
Failure to thrive means the baby does not gain weight and grow as expected. Poor bile acid production causes poor fat absorption and low energy intake.
-
Poor weight gain can be seen even before the diagnosis is made. The child may feed but still not grow well because nutrients are not absorbed normally.
-
Steatorrhea means fatty, bulky, greasy stool. This happens because bile acids are needed to digest and absorb dietary fat.
-
Pale stools may happen when bile is not reaching the intestine well. Caregivers may notice light, gray, or clay-colored stool.
-
Dark urine can happen because bilirubin leaves the body in urine during cholestasis.
-
Hepatomegaly, or enlarged liver, is common in cholestatic liver disease and may be found on exam.
-
Easy bruising or bleeding may happen when vitamin K is not absorbed well. This is an important clue in infants with cholestasis.
-
Vitamin A, D, E, and K deficiency can cause many problems because these fat-soluble vitamins need bile for absorption.
-
Irritability or poor feeding may appear in sick infants with cholestasis and liver dysfunction. These signs are not specific, but they often bring the child to medical attention.
-
Pruritus, or itching, can occur in cholestatic disorders, although it may not be the first sign in every infant.
-
Liver fibrosis or cirrhosis symptoms may develop later if the disease is not treated. This can include a firm liver, poor growth, and worsening liver failure.
-
Signs of rickets or weak bones may appear from vitamin D deficiency when fat absorption stays poor for a long time.
-
Neurologic problems related to vitamin deficiency can occur in some bile acid synthesis disorders, especially when diagnosis is delayed and malabsorption is severe.
Diagnostic tests
Doctors usually confirm this disease by combining clinical findings, urine bile acid analysis by mass spectrometry, and genetic testing for AKR1D1. The sections below use the categories you asked for. Some “electrodiagnostic” tests are not routine for every child, but they may be used when vitamin deficiency or nerve problems are suspected.
- General jaundice check. The doctor looks at the eyes and skin for yellow color. This is simple, but it is often the first sign that starts the liver work-up.
- Liver size check. The doctor feels and measures the liver to see if it is enlarged. Hepatomegaly supports a cholestatic liver disease.
- Growth assessment. Weight, length, and head growth are measured carefully. Poor growth and failure to thrive are very common clues in this disorder.
- Stool and urine color review. Doctors ask about pale stools and dark urine because these are classic signs of cholestasis.
- Bleeding and bruise check. The doctor looks for bruises, gum bleeding, or other signs of vitamin K deficiency and coagulopathy.
- Abdominal palpation. This bedside hand exam helps the clinician feel liver enlargement, firmness, and sometimes spleen enlargement. It is simple but very useful.
- Bedside neurologic exam. If fat-soluble vitamin deficiency is suspected, the doctor may check tone, reflexes, and developmental responses. This does not diagnose AKR1D1 deficiency alone, but it helps detect complications.
- Direct and total bilirubin. These blood tests show cholestasis and help separate conjugated jaundice from simple newborn jaundice.
- ALT and AST. These liver enzymes may be elevated and show liver cell injury, although they are not specific for AKR1D1 disease.
- GGT. In bile acid synthesis defects, GGT can be normal or not as high as expected, which can be a helpful clue.
- Prothrombin time or INR. These tests look for clotting problems, especially from vitamin K deficiency or liver dysfunction.
- Fat-soluble vitamin levels. Measuring vitamins A, D, E, and K helps show malabsorption and guides treatment.
- Urine bile acid profile by mass spectrometry. This is one of the most important tests. It looks for the abnormal bile acid intermediates that build up in AKR1D1 deficiency.
- Plasma or serum bile acid analysis. This can support the diagnosis and help monitor response to bile acid therapy.
- AKR1D1 genetic testing. Sequencing of the gene, often as part of a cholestasis panel, confirms the disease when pathogenic variants are found on both gene copies.
- Nerve conduction study. This is not a routine first-line test, but it may be used if severe vitamin deficiency causes suspected nerve damage.
- Electromyography, or EMG. This can help when a child has weakness or neuromuscular concerns related to long-term deficiency states. It is supportive, not disease-specific.
- Abdominal ultrasound. Ultrasound checks liver size, texture, bile ducts, and other causes of cholestasis such as structural blockage.
- Elastography when available. This imaging method looks for liver stiffness and can help estimate fibrosis in chronic disease.
- Hepatobiliary imaging in selected cases. Functional biliary imaging may be used to help exclude other disorders, especially when the diagnosis is not clear at the start.
Non-Pharmacological Treatments
-
Care by a pediatric liver specialist is one of the best non-drug treatments. This disease is rare, and mistakes are easy when care is not specialized. A liver team can follow growth, jaundice, stool color, bleeding risk, vitamin levels, liver tests, and signs of cirrhosis. The purpose is early correction of problems before permanent damage happens. The mechanism is not a chemical action; it works by fast recognition, tight monitoring, and good coordination of nutrition, medicines, and transplant care when needed. 2 3 7
-
Early diagnosis is almost a treatment by itself because delay can lead to cirrhosis, transplant, or death. Urine bile acid testing by mass spectrometry and genetic testing help confirm the disorder. The purpose is to start the correct therapy before the liver is badly scarred. The mechanism is simple: when doctors identify the exact bile acid defect, they can replace the missing bile acid and stop harmful mismanagement. 3 7 5
-
Frequent liver function monitoring is essential. Blood tests such as AST, ALT, bilirubin, GGT, alkaline phosphatase, and INR help show whether the liver is improving or worsening. The purpose is safety and treatment adjustment. The mechanism is early warning: lab changes can appear before the child looks much sicker. The FDA label for cholic acid also recommends close laboratory monitoring. 6
-
Regular nutrition review is important because cholestasis reduces fat absorption and can slow growth. The purpose is better weight gain, muscle growth, brain development, and healing. The mechanism is replacing calories and nutrients that the gut cannot absorb well during bile acid deficiency. 8 5
-
High-calorie feeding plans help babies and children who are not growing well. The purpose is to prevent failure to thrive. The mechanism is giving more energy than usual to overcome poor absorption and increased illness stress. 8 9
-
Use of medium-chain triglyceride-rich nutrition when advised may help some cholestatic patients because these fats are absorbed more easily than long-chain fats. The purpose is to improve calorie intake. The mechanism is simpler intestinal absorption with less dependence on bile micelles than ordinary fats. 9 8
-
Regular measurement of vitamins A, D, E, and K is a core supportive therapy. The purpose is to stop bleeding, bone disease, nerve injury, and eye problems before they become serious. The mechanism is surveillance and targeted correction, because vitamin deficiency is common in cholestasis. 8 10
-
Growth chart tracking helps doctors see whether treatment is working. The purpose is to detect hidden malnutrition. The mechanism is simple comparison over time of weight, length or height, and head growth in infants. 8 3
-
Stool and bleeding observation at home is useful. Pale stool, oily stool, dark urine, nosebleeds, gum bleeding, or easy bruising may mean worse cholestasis or vitamin K deficiency. The purpose is fast medical review. The mechanism is early symptom detection. 1 8
-
Avoiding fasting and poor intake is supportive, especially in infants. The purpose is to lower catabolic stress and worsening malnutrition. The mechanism is keeping energy supply more stable in a child whose digestion is already inefficient. 8
-
Bone health monitoring is important because vitamin D deficiency and chronic cholestasis can weaken bones. The purpose is prevention of rickets and fractures. The mechanism is regular review of vitamin status, growth, and sometimes bone studies when clinically needed. 8 10
-
Vision and eye review may be needed when vitamin A deficiency is suspected. The purpose is to prevent eye dryness and poor vision. The mechanism is early correction of deficiency-related complications. 8
-
Neurologic and developmental follow-up is useful because chronic malnutrition and vitamin deficiency can affect development. The purpose is early intervention for delays. The mechanism is screening and support rather than direct disease reversal. 10 3
-
Family genetic counseling is important because this is usually an autosomal recessive disorder. The purpose is risk explanation for future pregnancies and sibling testing. The mechanism is education and informed family planning. 4 2
-
Testing siblings when appropriate may identify affected children before severe symptoms begin. The purpose is early treatment. The mechanism is case finding in families at risk. 4 7
-
Careful review of all medicines and supplements is helpful because some products can stress the liver or confuse the picture. The purpose is liver safety. The mechanism is avoiding unnecessary hepatic burden and avoiding treatments that do not help this disorder. 6 5
-
Transplant center consultation when disease is advanced is a key non-drug step. The purpose is planning before liver failure becomes critical. The mechanism is timely referral for evaluation, not waiting until an emergency. 2 7
-
Regular ultrasound and liver assessment when clinically indicated help watch for cirrhosis, portal hypertension, or other structural problems. The purpose is staging disease severity. The mechanism is imaging-based follow-up. 2 7
-
Parent education is a real therapy. Families need to know danger signs, dosing mistakes, missed follow-up, and bleeding symptoms. The purpose is safer daily care. The mechanism is better adherence and earlier response to change. 6 8
-
Long-term follow-up even after improvement is needed because this is a chronic genetic disorder. The purpose is to keep liver health stable and prevent late complications. The mechanism is continuous reassessment of growth, labs, vitamins, and treatment response. 3 6
Drug Treatments
The main evidence-based drug is cholic acid. The FDA-approved product is CHOLBAM for bile acid synthesis disorders due to single-enzyme defects. The recommended dosage in the FDA label is 10 to 15 mg/kg/day by mouth once daily or in two divided doses. Its purpose is to replace missing primary bile acid, improve bile flow, help absorb fat and fat-soluble vitamins, and reduce production of toxic bile intermediates by feedback inhibition. Common adverse reactions listed in the label include diarrhea, reflux esophagitis, malaise, jaundice, skin lesion, nausea, abdominal pain, intestinal polyp, urinary tract infection, and peripheral neuropathy. The label also recommends close liver test monitoring and stopping therapy if liver function fails to improve or worsens. 6
Chenodeoxycholic acid (CDCA) has been reported in the medical literature as an effective primary bile acid replacement in some AKR1D1 patients, especially where individualized therapy is needed. Its purpose is also bile acid replacement and suppression of abnormal bile acid synthesis. Its mechanism is stronger feedback inhibition of bile acid synthesis than some other bile acids. However, this is not the main FDA-labeled drug for this condition in the United States, and the dose must be individualized by a specialist because excess dosing can be harmful. 11 12 3
Ursodeoxycholic acid (UDCA) is sometimes tried in cholestatic disease, but evidence suggests it is not the preferred definitive treatment for AKR1D1 deficiency because it does not correct the missing primary bile acid problem well enough. Some reports describe poor response until primary bile acid therapy was used, although there are rare exceptions. 11 12 13
Beyond bile acids, most “drug treatments” are really supportive medicines: vitamin K for bleeding risk, vitamin D for bone protection, vitamin A for vision and epithelial health, vitamin E for nerve and antioxidant support, and individualized multivitamin therapy. These drugs do not fix the AKR1D1 mutation, but they treat common consequences of cholestasis and malabsorption. Doses vary widely and should be based on age, weight, blood tests, and severity of deficiency, because cholestatic children often need individualized regimens rather than one fixed dose. 8 10
Because the evidence base is limited, it would be misleading to pretend there are 20 important proven disease-specific drugs for AKR1D1 deficiency. There are not. In practice, drug care usually includes cholic acid first, possible specialist-guided CDCA in select settings, and then vitamin replacement and complication treatment according to the patient’s needs. 6 3 2
Dietary Molecular Supplements
The most important dietary supplements are the fat-soluble vitamins A, D, E, and K, plus targeted nutrition support when needed. Vitamin A supports vision and epithelial tissue. Vitamin D supports calcium balance and bones. Vitamin E supports nerve and cell membrane protection. Vitamin K supports clotting. In cholestasis, blood levels should be monitored because absorption is poor and needs are highly variable. 8 10
Other supplements that may be considered by specialists include calcium, iron if deficiency exists, zinc if deficiency exists, essential fatty acid support, high-calorie modular feeds, and sometimes special vitamin formulations made to improve absorption in cholestatic children. These are functional supports, not cures. Their mechanism is to replace nutrients lost through malabsorption or poor intake. 8 9
There is no good evidence that herbal “liver cleansers,” immune boosters, or internet supplements treat AKR1D1 deficiency itself. Because the liver is already vulnerable, unproven supplements can be risky. Evidence-based supplementation in this disease means measured replacement of vitamins and nutrients that are truly low. 8 5
Immunity Booster, Regenerative, and Stem Cell Drugs
At present, no standard immunity booster drugs, regenerative drugs, or stem cell medicines are established treatments for AKR1D1 congenital bile acid synthesis defect. This is important to say clearly. The disease mechanism is a genetic enzyme defect in bile acid synthesis, so the effective treatment is bile acid replacement and liver support, not immune stimulation. 3 5
Supportive care may improve general health, but it should not be described as proven regenerative therapy. Research in rare metabolic liver disease continues, yet current routine care still centers on early diagnosis, cholic acid, nutrition, vitamin replacement, and transplantation when irreversible liver failure develops. 2 7 6
Surgeries and Procedures
There is no routine corrective surgery that fixes the AKR1D1 enzyme defect. The most important procedure is liver transplantation for patients with advanced liver failure, decompensated cirrhosis, or failure of medical therapy. It is done because the damaged liver can no longer work well enough to support life. 2 7
Other procedures may be needed only in selected patients, such as liver biopsy for diagnosis or staging, endoscopy if portal hypertension causes varices, feeding tube placement when severe malnutrition prevents growth, and management procedures for bleeding or transplant complications. These procedures treat complications, not the root enzyme defect. 3 8
Preventions
This inherited disease itself usually cannot be prevented after conception, but many complications can be prevented. The best prevention steps are: early diagnosis, prompt specialist care, early bile acid replacement, regular liver tests, regular vitamin checks, aggressive nutrition support, careful follow-up of growth, family genetic counseling, early transplant referral for advanced disease, and avoidance of unproven liver-stressing remedies. These steps lower the risk of cirrhosis, bleeding, malnutrition, and delayed treatment. 2 3 6
When to See Doctors
See a doctor urgently if a baby has yellow eyes or skin, dark urine, pale stool, poor feeding, poor weight gain, vomiting, easy bruising, bleeding, swollen belly, or unusual sleepiness. See a liver specialist quickly if cholestasis is suspected, especially when routine tests do not explain the problem. Early treatment gives the best chance for recovery. 1 7 2
What to Eat and What to Avoid
Helpful foods and feeding patterns usually include high-calorie nutrition, adequate protein, specialist-guided formula or feeds, foods that help meet vitamin needs, and nutrition plans adjusted to age and growth. Some children may benefit from MCT-containing nutrition under medical advice. 8 9
Things to avoid include fasting, poor intake, unproven herbal products, alcohol in older patients, random megadose supplements without testing, and stopping prescribed therapy on your own. The diet should be individualized because malabsorption severity differs from patient to patient. 8 6
FAQs
1. Is this disease genetic? Yes. It is usually inherited in an autosomal recessive pattern. 4
2. Is it rare? Yes, it is very rare. 2
3. What organ is mainly affected? The liver, though nutrition and vitamins are also affected. 1
4. What is the key approved medicine? Cholic acid. 6
5. What dose is commonly used? FDA labeling gives 10 to 15 mg/kg/day. 6
6. Can vitamins be low? Yes, especially A, D, E, and K. 8
7. Can it cause bleeding? Yes, especially with vitamin K deficiency and liver dysfunction. 10
8. Can it cause poor growth? Yes. 1
9. Is UDCA enough? Often no; primary bile acid replacement is usually more appropriate. 11 12
10. Can some patients need transplant? Yes, especially if diagnosis is late or liver disease is advanced. 2
11. Is early treatment important? Very important. 7
12. Are stem cell drugs standard? No. 3
13. Can adults have it too? Yes, though it often starts in infancy. 3
14. Should siblings be checked? Often yes, after specialist advice. 4
15. Can children improve with treatment? Yes, many improve greatly when diagnosed and treated early. 3 7
Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.
The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members
Last Updated: March 10, 2025.
